Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

DISEASE CHARACTERISTICS:

* Histologically confirmed adenocarcinoma of the prostate, meeting the following criteria:

  * Metastatic disease
  * Objective progression or rising prostate-specific antigen (PSA) despite androgen-deprivation therapy and antiandrogen withdrawal
* Patients with rising PSA must demonstrate a rising trend with 2 successive elevations at a minimum interval of 1 week

  * Minimum PSA of 5 ng/mL or new areas of bony metastases on bone scan required if no measurable disease
  * No minimum PSA for measurable disease
* Must have received ≤ 1 prior docetaxel-based chemotherapy for metastatic disease
* No known CNS disease or brain metastases
* Testosterone \< 0.5 ng/mL (castrate level)

  * Concurrent luteinizing-hormone releasing-hormone agonist allowed to maintain castrate level

PATIENT CHARACTERISTICS:

* Zubrod performance status 0-1
* Life expectancy ≥ 12 weeks
* Absolute neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin ≥ 8.0 g/dL
* Bilirubin normal
* Creatinine ≤ 2 mg/dL OR creatinine clearance ≥ 50 mL/min
* Urine protein:creatinine ratio ≤ 1.0 OR proteinuria ≤ 2+ by urine dipstick OR ≤ 1 g protein/24-hour urine collection
* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment
* No significant traumatic injury within the past 28 days
* Adequately controlled hypertension (defined as systolic blood pressure \[BP\] ≤ 150 mm Hg and/or diastolic BP ≤ 100 mm Hg on antihypertensive medications)
* No history of hypertensive crisis or hypertensive encephalopathy
* No New York Heart Association class II-IV congestive heart failure
* No myocardial infarction or unstable angina within the past 6 months
* No stroke or transient ischemic attack within the past 6 months
* No significant vascular disease (e.g., aortic aneurysm, aortic dissection)
* No symptomatic peripheral vascular disease
* No evidence of bleeding diathesis or coagulopathy
* No prior malignancy except adequately treated skin cancer or any other cancer in complete remission for ≥ 2 years
* Able to swallow and retain capsules
* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
* No serious nonhealing wound, ulcer, or bone fracture
* No known hypersensitivity to any component of bevacizumab
* No history of allergic reactions attributed to compounds of similar chemical or biological composition to bevacizumab
* No uncontrolled intercurrent illness, including, but not limited to, any of the following:

  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Cardiac arrhythmia
* No psychiatric illness or social situation that would preclude compliance with study requirements
* No HIV positivity
* No immune deficiency

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* More than 4 weeks since prior flutamide
* More than 6 weeks since prior bicalutamide or nilutamide
* At least 4 weeks since prior radiotherapy
* At least 2 weeks since prior minor surgery
* More than 7 days since prior core biopsy or minor surgery (excluding placement of a vascular access device)
* More than 28 days since prior major surgery or open biopsy (8 weeks if high-risk procedure such as liver resection, thoracotomy, or neurosurgery)
* Concurrent low-dose aspirin (≤ 325 mg/day) allowed
* Concurrent anticoagulants allowed if patient has been on therapy ≥ 4 weeks and has no acute thromboembolic activity
* No concurrent major surgery
* No concurrent aprepitant
* No concurrent immunosuppressive therapy
* No concurrent combination anti-retroviral therapy for HIV-positive patients
* No other concurrent antitumor therapy (including radiotherapy)
* No other concurrent investigational agents